At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Mar 16, 2015
Santa Rosa, Ca., March --- March 16, 2015 – Ruthigen, Inc. (NASDAQ: RTGN) (“Ruthigen”), and Pulmatrix, Inc., (“Pulmatrix”), a Lexington, Massachusetts based clinical stage...
May 5, 2014
Results Demonstrated the Enablement of High Drug Load Delivery with iSPERSE Dry Powder Delivery Technology
Lexington, MA, May 5, 2014 – Pulmatrix today presented data at the 2014 Respiratory Drug Delivery Conference in Fajardo, Puerto Rico. The poster presentation includes development data on...
May 5, 2014
Clinical Results Highlight Advantages of the iSPERSE Inhaled Dry Powder Delivery Platform
over Conventional Lactose Blend Technologies
Lexington, MA, May 5, 2014 – Pulmatrix today announced the successful completion and positive results of the second part of a two-part Phase 1B clinical study in chronic obstructive...